ASH Recent News
Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure
Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting
Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data
Vetr Upgrades Alnylam On News Of Streamed Press Conference
Biotech Winners And Losers From ASH Conference
8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting
A Primer On Endpoints: Global Blood Therapeutics
UniQure Vs. Spark Therapeutics: One Has Better Timing, The Other Has Better Efficacy
Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy
EXCLUSIVE With Ziopharm CEO: Here's Why Our Genetic Programming Is Different From Competitors
One Way To Bet On The American Society Of Hematology's Meeting Next Month